President Barrack Obama commented on anabolic steroids during his first presidential press conference in response to a question by Washington Post reporter Michael A. Fletcher. Fletcher surprisingly asked President Obama about Alex Rodriguez’ admission of anabolic steroid use during his Major League Baseball career, “What is your reaction to Alex Rodriguez’s admission that he used steroids as a member of the Texas Rangers?” (”Obama’s First News Conference Covers A Range Of Issues,” February 9)
“I think it’s depressing news on top of what’s been a flurry of depressing items when it comes to Major League Baseball. And if you’re a fan of Major League Baseball, I think it tarnishes an entire era to some degree. And it’s unfortunate, because I think there are a lot of ball players who played it straight.
“And the thing I’m probably most concerned about is the message that it sends to our kids. What I’m pleased about is Major League Baseball seems to finally be taking this seriously, to recognize how big of a problem this is for the sport, and that our kids, hopefully, are watching and saying ‘You know what? There are no short cuts.’ That when you try to take short cuts, you may end up tarnishing your entire career. And your integrity’s not worth it. That’s the message I hope is communicated.”
The Washington Post asked the only question that did not involve domestic or foreign policy and was widely criticized as being inappropriate given the importance of other issues discussed during the prime-time presidential press conference. Read more
The pharmaceutical giant Solvay Pharmaceuticals is unapologetic about its actions aimed at maintaining its monopoly on the phamaceutical testosterone gel Androgel (an anabolic-androgenic steroid). Solvay has “bought off” generic companies who planned to introduce inexpensive, generic versions of Androgel. The generic companies Watson Pharmaceuticals, Par Pharmaceutical, and Paddock Laboratories were prepared to offer a cheap generic testosterone gel as early as 2006 after the FDA granted Watson final approval for its generic product in January 2006. Solvay paid the generic companies a substantial amount of money to delay their entry into the generic Androgel marketplace until 2015.
The threat of generic competition would have decimated Solvay’s sales of Androgel; AndroGel has been their top-selling product with sales exceeding $300 million in 2006 and $400 million in 2007. Generic competition to Solvay’s flagship product Androgel could reduce the price of testosterone gel as much as 90% when compared to brand name Androgel. The payments to delay entry into the generic marketplace aka “pay-for-delay” settlements would be highly profitable for Solvay by extending brand name patent protection for several years. The windfall profits would come at the expense of consumers and federal taxpayers costing them billions of dollars Read more
Advocates of steroid law reform are very disappointed that Democratic presidential candidate Barrack Obama selected Senator Joseph Biden as his vice presidential nominee. Senator Biden was the chief architect of the Anabolic Steroid Control Act of 1990 that criminalized the possession of anabolic steroids for non-medical purposes. Biden also wrote the Anabolic Steroid Control Act of 2004 which opened the door for significantly harsher penalties for steroid possession and steroid distribution; this has resulted in the increased prosecution of steroid users over the past few years who are treated as dangerous criminals with the worst penalties for the non-medical use of steroids in history. Senator Biden has been on his anti-steroid crusade for almost two decades.
Steroid law expert Rick Collins revealed in testimony to the United States Sentencing Commission that the typical non-medical steroid users has been misrepresented to the public and to legislators.
